 BURLINGTON, Mass., March 01, 2021 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN today announced the U.S. Food and Drug Administration FDA cleared the Investigational New Drug IND application for FX301, a locally administered NaV1.7 inhibitor known as funapide, formulated for extended-release in a thermosensitive hydrogel. The selective pharmacology of funapide holds the potential to provide effective non-opioid pain relief for at least 3 to 5 days, while preserving extremity motor function which is typically compromised by local anesthetic peripheral nerve block. 